Watch Ticker

Galectin Therapeutics Inc.

Go to Galectin Therapeutics Inc. Website

$3.47

(%)

Live

Previous Close

$3.47

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$214.8 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (G...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Wall Street Breakfast - Wall Street Breakfast: The Week Ahead

Geopolitical tensions in the Middle East, earnings reports from major companies, and the upcoming bitcoin halving event are set to drive market focus this...

Related tickers: NFLX, GS, MS, BAC, UNH, JNJ, TRV, PG, AXP, SCHW, MTB, RIO, UAL, ABT, USB, KMI, VFS, LVS, CSX, BX, ALLY, TSM, ISRG, NKLA, RIVN, IZM, GALT, PERI, SIRI, GL, CPRI, TPR, ALAB, RDDT, AUNA, WBUY, GDTC, SONY, VZ, SBGI, BMR, IDCC, BLZE, BIDU, GP, BNTC.

Read Full Article

Galectin Therapeutics Inc. - Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.

Related tickers: GALT.

Read Full Article

Trending Tickers

LASE

XNAS

$2.07

(%)

PACW

XNAS

$7.54

(%)

SMFL

XNAS

$3.37

(%)

XNYS

$73.53

(%)

MLGO

XNAS

$0.00

(%)